Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Orchard Therapeutics Plc ADR
(NQ:
ORTX
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Jan 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Orchard Therapeutics Plc ADR
< Previous
1
2
Next >
Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024
May 07, 2024
Eight presentations showcase the broad applicability of HSC gene therapy to address rare neurometabolic diseases and beyond
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List
May 03, 2024
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy
March 20, 2024
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.
March 18, 2024
One-time treatment with Lenmeldy has shown the potential to restore enzymatic function to stop or slow disease progression, with up to 12 years of follow-up (median 6.76 years)
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome
February 05, 2024
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposium
February 02, 2024
Three oral presentations and seven posters highlight transformative potential of HSC gene therapy and newborn screening to address severe neurometabolic diseases
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to Libmeldy
January 25, 2024
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases
January 24, 2024
Acquisition enriches Kyowa Kirin’s portfolio, enables the development of numerous promising candidates with a clinically differentiated platform, and helps to resource ongoing and future launches of...
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Receives Swissmedic Approval for Libmeldy in Early-onset MLD
December 11, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH
November 30, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
ORCHARD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Orchard Therapeutics plc - ORTX
November 28, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business Accomplishments
November 13, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-of-concept Study of OTL-203 in MPS-IH at ESGCT 2023
October 26, 2023
New clinical data beyond previously reported neurological and skeletal results demonstrate favorable outcomes for multiple disease manifestations not effectively addressed by the current standard of...
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Announces Multiple Presentations at ESGCT 2023
October 24, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
ORCHARD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Orchard Therapeutics plc - ORTX
October 06, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: SP® Plus Corporation (Nasdaq - SP), Orchard Therapeutics plc (Nasdaq - ORTX), Summit Materials (NYSE - SUM)
October 05, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Orchard Therapeutics PLC (NASDAQ: ORTX) Sets New 52-Week High in Thursday Session
October 05, 2023
Via
Investor Brand Network
ORTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Orchard Therapeutics plc Is Fair to Shareholders
October 05, 2023
From
Halper Sadeh LLC
Via
Business Wire
Kyowa Kirin to Acquire Orchard Therapeutics
October 05, 2023
From
Orchard Therapeutics (Europe) Limited; Kyowa Kirin Co., Ltd.
Via
GlobeNewswire
Are Gene Therapy Stocks The Market's Next Big Winners?
September 25, 2023
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Orchard Therapeutics Announces Acceptance of Biologics License Application for OTL-200 in MLD and Receives Priority Review
September 18, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Announces Presentation of Data Comprising the Clinical Package for the OTL-200 BLA in MLD at the SSIEM Annual Symposium 2023
August 31, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Completes Submission of Biologics License Application for OTL-200 in MLD to U.S. FDA
August 03, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Strongly Supports Enactment of Newborn Metabolic Screening Act in Illinois, Adding Metachromatic Leukodystrophy to Statewide Panel
August 02, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics to Webcast Conference Call of Second Quarter 2023 Financial Results
July 25, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Announces Second Closing of Strategic Financing, Resulting in $34 Million of Additional Capital
June 26, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics to Present at Stifel’s Genetic Medicines Day
May 24, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Announces Positive Clinical and Preclinical Data in Programs Targeting Neurometabolic and CNS Disorders at ASGCT
May 19, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Presents Data from Research Programs at ASGCT Demonstrating the Ability of HSC Gene Therapy to Address Larger Indications
May 18, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Reports First Quarter 2023 Financial Results and Announces Initiation of Rolling Submission for Biologics License Application of OTL-200 for Metachromatic Leukodystrophy to U.S. FDA
May 15, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.